Bleeding under Voltaren®
The commercial product Voltaren® contains the active ingredient diclofenac. Its mode of action explains a relatively increased risk of bleeding.Voltaren® inhibits two enzymes. By inhibiting one enzyme, hemostasis is inhibited.
This leads to a colloquial blood thinning. This results in a relatively increased risk of bleeding. This tendency to bleed can affect the skin and mucous membranes as well as internal organs such as the stomach and intestines.
However, the active ingredient Diclofenac . inhibits hemostasis to a lesser extent than other active ingredients from the same substance class. Accordingly, the risk of bleeding is lower.
However, if other drugs are taken in addition, which can trigger an increased tendency to bleed, the risk of bleeding increases. For example, the risk of bleeding can be increased when combined with active ingredients from the same substance class or with so-called anticoagulants such as Marcumar®. A combination with selective serotonin reuptake inhibitors (SSRI ́s) can also increase the risk of bleeding side effects.
Summary
The pain medication Voltaren® contains the active ingredient diclofenac. It belongs to the group of so-called “non-steroidal anti-inflammatory drugs”, or NSAIDs for short. The spectrum of activity of Voltaren® includes pain relief, inflammation inhibition and fever reduction.
The main areas of application are primarily pain, bruises or strains caused by injuries to the musculoskeletal system or sports accidents and rheumatic diseases. Depending on the form of administration, it can be used internally or externally, as well as for mild to moderately severe acute, i.e. suddenly occurring to chronic, i.e. permanent pain.
All articles in this series: